LETTER TO THE EDITOR

Cardiotoxicity Related to Long-Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

To the Editor:

Since its approval, trastuzumab (Herceptin, F. Hoffmann-La Roche Ltd., Basel Switzerland) has dramatically improved outcomes of patients with Human Epidermal growth factor Receptor 2 (HER2+) metastatic breast cancer (MBC) and has ushered in a new era in clinical practice, providing innovative insights on long-term treatment (1–3). Indeed, several studies have shown that long-term HER2 suppression should be maintained in HER2+ MBC both beyond disease response (4,5) and progression (6,7). Therefore, a growing number of patients have been receiving long-term trastuzumab administration, as maintenance monotherapy or in combination with multiple lines of chemotherapy.

However, over the last 10 years, trastuzumab cardiotoxicity, ranging from asymptomatic left ventricular dysfunction to congestive heart failure (1,8,9), has emerged as a critical concern. Differently than anthracycline, trastuzumab cardiotoxicity is neither dose-related nor cumulative and appears generally reversible (6). Its pathogenesis seems partly due to antibody-directed cellular cytotoxicity, to HER2 downregulation in cardiomyocytes and, as recently demonstrated, to destabilization of mitochondrial membrane with Adenosin Triphosphate depletion and subsequent cardiomyocyte contractile dysfunction (4).

The large trastuzumab adjuvant trials, including the recent analysis of 2-year arm of HERA trial, showed a low incidence of Cardiac Events (CEs) during adjuvant trastuzumab and demonstrated that the cumulative incidence of CEs tends to plateau after treatment completion, thus suggesting that cardiotoxicity occurs early and mainly while on treatment (5,9). However, these data refer to patients strictly selected on the basis of cardiac risk factors and exposed to trastuzumab for a well-defined time. Conversely, in metastatic setting the cardiac safety of prolonged trastuzumab administration have yet to be clarified, despite an increasing number of patients having received trastuzumab for several years. Data on incidence, onset, and outcome of cardiotoxicity in MBC patients receiving long-term trastuzumab therapy are lacking. Notably, very few studies have weighed benefits and cardiac harms of prolonged trastuzumab therapies in a “real world” MBC population, in which comorbidities, previous treatments and general aging could represent heavy cardiac risk factors (7,10–12).

To determine whether duration of trastuzumab and the presence of cardiac risk factors can affect the cardiac safety of trastuzumab in metastatic setting, we conducted a retrospective analysis of 62 HER2+ MBC patients treated with trastuzumab and at least one concomitant chemotherapy regimen at our Institution from December 2003 to June 2012. The median age was 52 years (range 29–76 years); the median cumulative time receiving trastuzumab resulted 29.5 months (range 3–99 months). Forty patients (64.5%) received trastuzumab without interruption from the diagnosis of MBC, for a median time of 29 months (range 3–99 months); in the remaining patients 1 or 2 interruptions were recorded with a median interruption time of 7 months (range 2–30 months). According to previous published data (9,10), we evaluated, in univariate Cox regression analysis, the following variables as potential cardiac risk factors: age at start of trastuzumab, body mass index (BMI, <25 versus ≥25 kg/m²), antihypertensive therapy, history of cardiac disease, diabetes, smoking, radiotherapy on the left chest wall, prior exposure to anthracyclines, baseline Left Ventricular Ejection Fraction (LVEF), continued/interrupted trastuzumab exposure and duration of concomitant exposure to chemotherapy and trastuzumab. In univariate analysis
significant risk factors for trastuzumab-related cardiotoxicity resulted: history of cardiac disease (hazard ratio [HR] 6.81, 95% CI: 1.38–33.54) and smoking (HR 5.23, 95% CI: 1.40–19.49). In multivariate analysis smoking remained positively correlated with the risk of cardiotoxicity, but this trend was not statistically significant (HR 3.89, 95% CI: 0.88–17.17, \( p = 0.073 \)), probably due to the limited sample size. To our knowledge, such correlation was reported only in the adjuvant setting and it seems related to a negative effect of cigarette smoking on myocardial longitudinal strain (13,14).

In our cohort, a high percentage of patients presented at least one comorbidity (54.8%), received previous anthracycline-based therapies (67.7%) and were older than 60 at the start of trastuzumab administration (35.5%). Despite the long-term trastuzumab exposition and the high rate of potential risk factors, we observed a low incidence of CEs (17.7%). Specifically, three patients (4.8%) experienced an asymptomatic LVEF drop of at least 20% points compared with the baseline, with a LVEF not below normal limits; five patients (8.1%) had a grade 2 cardiac toxicity (LVEF range, 40–50%) and three (4.8%) experienced a grade 3 cardiac toxicity (symptomatic CHF, LVEF range, 20–40%). All of them, except one, quickly recovered after temporary trastuzumab discontinuation with or without appropriate cardiologic therapy. These data were similar to those shown in previous series of trastuzumab administration beyond progression (7,11,12), but lower than that previously reported in MD Anderson Cancer Center cohort, in which a 28% rate of CEs was detected (10). The fairly low incidence of CEs might be due to both our limited sample size and the inclusion of patients receiving trastuzumab for less than 1 year. To better understand the potential interaction between cumulative trastuzumab exposure and cardiotoxicity, we compared the distribution of CEs over different times of trastuzumab administration. Since in our cohort the majority of CEs occurred within the first 36 months (63.6%), similarly to the data reported in the MD Anderson analysis (10), we hypothesized a plateau phenomenon after 3 years of treatment (Fig. 1). Therefore, we compared the distribution of CEs between those patients receiving trastuzumab for up to 36 months and those continuing for more than 36 months, 7/43 (16.3%) and 4/19 (21%), respectively. The difference in CEs rate between those two groups was not statistically significant (\( p = 0.724 \)), likely due to the limited sample size. However, the distribution of CEs in our analysis suggests that the likelihood of trastuzumab cardiotoxicity does not increase over time nor does it seem related to cumulative trastuzumab exposure. These data are in accordance with those reported in the GBG 26 trial, which evaluated the combination capecitabine with trastuzumab versus capecitabine alone in HER2+ MBC beyond progression. It showed a not statistically significant increase in CEs over a median cumulative time of trastuzumab exposure up to 72 weeks (3). Conversely, Morabito and colleagues, reviewing 37 published clinical trials of trastuzumab in HER2+ MBC, concluded that time receiving trastuzumab was associated with an increased risk of developing any grade of cardiotoxicity (15). However in the majority of the evaluated studies, patients received trastuzumab for up to 40 weeks and thus it is likely that the

![Figure 1. Time to cardiac event.](image-url)
plateau phenomenon was not reached yet (16). Moreover, in our analysis, the relatively early onset of trastuzumab cardiotoxicity also suggests some consideration on the appropriate cardiac follow-up in MBC patients receiving prolonged trastuzumab administration. In this setting, reliable recommendations for both time and optimal modality of cardiac monitoring and thresholds for trastuzumab discontinuation are lacking (17). In this regard, our findings suggest that cardiac monitoring could be safely delayed in patients with low cardiovascular risk who are continuing uneventfully trastuzumab therapies for more than 36 months.

In conclusion, in daily clinical practice physicians are increasingly called to balance benefits and harms of prolonged trastuzumab-based therapies, especially for patients with several significant cardiovascular risk factors, including elderly people and patients previously exposed to anthracycline. Moreover, the majority of upcoming compounds directed against HER2+ breast cancer are being administered in combination with trastuzumab. Therefore, further studies with larger sample are warranted to provide a thorough knowledge of cardiotoxicity related to long-term trastuzumab administration.

Acknowledgments

We would like to thank Mrs. Madeleine Penrice for her kind assistance with English translation.

FUNDING

Financial support was not provided.

CONFLICTS OF INTEREST

None to declare.

Barbara Pistilli, MD*
Andrea Marcellusi, MSc†,‡
Luciano Latini, MD§
Roberto Acardi, MD§
Benedetta Ferretti, MD¶
Giovanni Benedetti, MD*†
*Oncology Unit
Macerata Hospital
Macerata
Italy;
†Centre for Health Economics and Management
(CHEM)
Faculty of Economics

Tor Vergata University
Rome
Italy;
‡Department of Statistics
University of Rome “Sapienza”
Rome
Italy;
§Cardiology Hemodinamic Unit
Macerata Hospital
Macerata
Italy;
¶Oncology Unit
San Severino Hospital
San Severino
Italy

REFERENCES

1. Slamon DJ, Leland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
2. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722–30.
3. von Minckwitz G, du Bois A, Schimdt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999–2006.
4. Albini A, Cesana E, Donatelli F, et al. Cardiotoxicity in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol 2011;7:693–704.
5. Goldhirsch A, Piccart-Gebhart MJ, Proctor M, et al. HERA TRIAL: 2 years vs 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow-up. Cancer Res 2012;72 (suppl 3):AbstractS6-5.
6. Ewer MS, Voolertich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820–6.
7. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063–70.
8. Piccart-Gebhart MJ, Proctor K, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.
9. Romond EH, Jeong J-H, Rastogi P, et al. Seven-Year follow-up assessment of cardiac function in NSABP31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792–9.
10. Guarnieri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107–15.
11. Adamo V, Franchina T, Adamo B, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann of Oncol 2007;18(6s):11–5.
12. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120–5.

13. Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009;117:357–64.

14. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701–7.

15. Morabito A, Piccirillo MC, De Maio E, et al. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased? J Clin Oncol 2009;27:e123.

16. von Minckwitz G, Nekjudova V, Loibl S. Reply to A. Morabito et al. and G. Valbrega et al. J Clin Oncol 2009;27:e124–5.

17. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684–92.